The carnage in the biotech space in Q4 of last year was devastating to a lot of portfolios, and many of the stocks in the space became victims of aggressive tax-loss selling before year end to add insult to injury. But, rejoice, dear investor! That just means we have some great values lying around on […]
CLVS
Sarepta Therapeutics’ Eteplirsen Study Reveals Benefits to Patients (SRPT)
Sarepta Therapeutics (NASDAQ: SRPT), an RNA-based therapeutics company that develops drugs to treat serious, life-threatening, rare and infectious diseases, announced at the Action Duchenne meeting in London that patients treated with eteplirsen continue to do well. Benefits to Patients Sarepta’s Chief Medical Officer, Dr. Ed Kaye, was speaking about the results from the phase II […]
Recent Stories
Energy Transfer (NYSE:ET) Invokes Force Majeure To Prevent Customers From Abandoning Expansion Of Dakota Access Pipeline
Oracle Corporation (NASDAQ:ORCL) Opens Second Oracle Cloud Infrastructure (OCI) Region In India
Will CBD Become Robinhood’s Next Focus? (YCBD, NEPT, MCTC, ACB, MJNA)
Macy’s Inc (NYSE:M) and J C Penney Company Inc (OTCMKTS:JCPNQ) To Consider Reinventing Their Business Operations
Intel Corp (NASDAQ:INTC) Acquires $253.5 Million Interest in Reliance Jio Platforms